Delamanid

This image is provided by the National Library of Medicine.

WikiDoc Resources for Delamanid
Articles
Most recent articles on Delamanid Most cited articles on Delamanid Review articles on Delamanid Articles on Delamanid in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Delamanid Images of Delamanid Photos of Delamanid Podcasts & MP3s on Delamanid Videos on Delamanid
Evidence Based Medicine
Cochrane Collaboration on Delamanid Bandolier on Delamanid TRIP on Delamanid
Clinical Trials
Ongoing Trials on Delamanid at Clinical Trials.gov Trial results on Delamanid Clinical Trials on Delamanid at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Delamanid NICE Guidance on Delamanid NHS PRODIGY Guidance FDA on Delamanid CDC on Delamanid
Books
Books on Delamanid
News
Delamanid in the news Be alerted to news on Delamanid News trends on Delamanid
Commentary
Blogs on Delamanid
Definitions
Definitions of Delamanid
Patient Resources / Community
Patient resources on Delamanid Discussion groups on Delamanid Patient Handouts on Delamanid Directions to Hospitals Treating Delamanid Risk calculators and risk factors for Delamanid
Healthcare Provider Resources
Symptoms of Delamanid Causes & Risk Factors for Delamanid Diagnostic studies for Delamanid Treatment of Delamanid
Continuing Medical Education (CME)
CME Programs on Delamanid
International
Delamanid en Espanol Delamanid en Francais
Business
Delamanid in the Marketplace Patents on Delamanid
Experimental / Informatics
List of terms related to Delamanid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Delamanid (USAN, codenamed OPC-67683) is an experimental drug for the treatment of multi-drug-resistant tuberculosis. It works by blocking the synthesis of mycolic acids in Mycobacterium tuberculosis, the organism which causes tuberculosis, thus destabilising its cell wall. In phase II clinical trials, the drug was used in combination with standard treatments, such as four or five of the drugs ethambutol, isoniazid, pyrazinamide, rifampicin, aminoglycoside antibiotics, and quinolones. Healing rates (measured as sputum culture conversion) were significantly better in patients who additionally took delamanid. The European Medicines Agency (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness.

See also

• PA 824, a related drug